Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- WEBSITE NEWS
November 18, 2002
- Pramipexole Reported as 1st-Line Treatment for Parkinson's Disease
November 18, 2002
- Azwell Taking Tougher Stance in Price Negotiations
November 18, 2002
- Boehringer Ingelheim, ImmunoGen Start Trial on New Anticancer Agent
November 18, 2002
- JPMA Exchanges Opinions with ABPI, SNIP
November 18, 2002
- Zyvox Effective against Diabetic Foot Infections: Pharmacia
November 18, 2002
- New Chugai Is Enjoying Synergism: President Nagayama
November 18, 2002
- Over 100 Mil. Prescriptions Issued for Pharmacia's Xalatan
November 18, 2002
- Consumers Want More Info from Drug Makers: JPMA Survey
November 18, 2002
- GSK Reports Results of Major Survey on COPD
November 18, 2002
- MPC: Merger Synergism Boosts Sales, Profits
November 18, 2002
- DIAGNOSTIC NEWS IN BRIEF
November 18, 2002
- Arrow Japan to Diversify Business from Critical Care Products
November 18, 2002
- Terumo: Sales Up 3.4% in Japan, 8.1% Overseas
November 18, 2002
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
November 18, 2002
- OTC NEWS IN BRIEF
November 18, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
November 18, 2002
- Kowa to Codevelop Arteriosclerosis Drugs with GENFIT of France
November 18, 2002
- REGULATORY NEWS IN BRIEF
November 18, 2002
- Market Must Be Attractive to Invite Investment from Abroad: JPMA President
November 18, 2002
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…